In a Healio exclusive, Gideon Hirschfield, PhD, MB BChir, the Lily and Terry Horner Chair in Autoimmune Liver Disease Research at University of Toronto, discusses key considerations when diagnosing ...
(BPT) – Imagine waking up every day feeling utterly exhausted, no matter how much sleep you get. Now, add an unbearable itch that just won’t go away, dry eyes and mouth, and stomach pain. This is the ...
Given the nonspecific clinical presentation and laboratory findings, the diagnosis of recurrent PBC can be difficult. Numerous entities may present with cholestatic abnormalities in hepatic ...
Data from Phase 3 REGENERATE study supporting positive benefit-risk profile of obeticholic acid (OCA) in liver fibrosis due to NASH to be featured in late-breaker podium presentation Analysis ...
Patients with primary biliary cholangitis and moderate-to-severe pruritus who received seladelpar over 6 months experienced a ...
"PBC is one of those liver diseases where you can have cirrhosis and liver failure if you don't do anything about it in a matter of 10 to 15 years," said Lucy Mathew, NP, of Cedars Sinai in Los ...
Content developed independently by our editors and supported by our partners. Carrington Garvin had been living the fun-packed life of a typical 21-year-old in Las Vegas—dating, working for a gaming ...
Primary biliary cholangitis (PBC) is an autoimmune disease that causes the destruction of bile ducts within the liver. The loss of bile ducts results in bile acid buildup, which causes inflammation ...
Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of two per 100,000 people per year and an estimated prevalence of 15 per ...
PARIS, FRANCE, 07 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug ...
Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results